Literature DB >> 488753

Value of sigmoidoscopy and biopsy in detection of carcinoma and premalignant change in ulcerative colitis.

R H Riddell, B C Morson.   

Abstract

Of 111 carcinomas developing in 73 patients with ulcerative colitis, 46 (41.5%) arose in the rectum where they are directly accessible to sigmoidoscopy. Fifty-eight per cent of single carcinomas developed in the rectum. The extent and frequency of rectal dysplasia was assessed by examining slides of rectal mucosa with an eyepiece micrometer. Slides from 46 patients with carcinoma and 22 patients with dysplasia but no carcinoma in whom proctectomy or proctocolectomy had been carried out were examined by this method. Thirteen of 15 patients with carcinoma of the colon (87%) and 21/22 patients (95%) with large bowel dysplasia showed evidence only of rectal dysplasia. However, there was marked variability in the proportion of dysplastic rectal mucosa even in those patients with rectal carcinoma, while in some patients dysplasia was limited to a small focus. Because of the possibility of false negative biopsies due to sampling error, multiple biopsies should be taken to detect dysplasia. Their state should be recorded and deliberately varied at subsequent visits. Careful sigmoidoscopy and multiple biopsies in this study had potential value as an aid in the detection of 85-90% of all carcinomas. In practice the figure would almost certainly be lower due to intrinsic bias (see discussion) so that, although regular sigmoidoscopy and biopsy would be of great value when colonoscopy is not available, the latter should be included in any long-term programme of carcinoma prevention.

Entities:  

Mesh:

Year:  1979        PMID: 488753      PMCID: PMC1412513          DOI: 10.1136/gut.20.7.575

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Colonoscopy. Inefficacy for early carcinoma detection in patients with ulcerative colitis.

Authors:  T D Crowson; W F Ferrante; J B Gathright
Journal:  JAMA       Date:  1976-12-06       Impact factor: 56.272

2.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1964-02       Impact factor: 23.059

3.  Precancer and carcinoma in chronic ulcerative colitis. A histopathological and clinical investigation.

Authors:  L Hultén; J Kewenter; C Ahrén
Journal:  Scand J Gastroenterol       Date:  1972       Impact factor: 2.423

4.  Prospective study of outpatients with extensive colitis.

Authors:  J E Lennard-Jones; J J Misiewicz; J A Parrish; J K Ritchie; E T Swarbrick; C B Williams
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

5.  "Precancer" lesions in ulcerative colits. A retrospective study of rectal biopsy and colectomy specimens.

Authors:  J H Yardley; D F Keren
Journal:  Cancer       Date:  1974-09       Impact factor: 6.860

Review 6.  The precarcinomatous phase of ulcerative colitis.

Authors:  R H Riddell
Journal:  Curr Top Pathol       Date:  1976

7.  Cancer in colitis: assessment of the individual risk by clinical and histological criteria.

Authors:  J E Lennard-Jones; B C Morson; J K Ritchie; D C Shove; C B Williams
Journal:  Gastroenterology       Date:  1977-12       Impact factor: 22.682

8.  Rectal biopsy and precancer in ulcerative colitis.

Authors:  H E Myrvold; N G Kock; C Ahrén
Journal:  Gut       Date:  1974-04       Impact factor: 23.059

9.  Tissue demonstration of carcinoembryonic antigen (CEA) in ulcerative colitis.

Authors:  P Isaacson
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

10.  In-situ and invasive carcinoma of the colon in patients with ulcerative colitis.

Authors:  D J Evans; D J Pollock
Journal:  Gut       Date:  1972-07       Impact factor: 23.059

View more
  10 in total

1.  Rectal mucosal dysplasia in Crohn's disease.

Authors:  B I Korelitz; G Y Lauwers; S C Sommers
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

2.  Crypt cell production rate in ulcerative proctocolitis: differential increments in remission and relapse.

Authors:  A Allan; J B Bristol; R C Williamson
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

3.  Immunohistochemical evaluation of carcinoembryonic antigen, secretory component, and epithelial IgA in ulcerative colitis with dysplasia.

Authors:  T O Rognum; K Elgjo; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

4.  Carcinoma complicating ulcerative colitis: multidisciplinary clinical conference in gastroenetrology.

Authors: 
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

5.  The occurrence of severe epithelial dysplasia and its bearing on treatment of longstanding ulcerative colitis.

Authors:  J Kewenter; L Hultén; C Ahrén
Journal:  Ann Surg       Date:  1982-02       Impact factor: 12.969

6.  DNA aneuploidy in a case of rectosigmoid adenocarcinoma complicated by ulcerative colitis.

Authors:  K Makiyama; M Tokunaga; M Itsuno; W Zea-Iriarte; K Hara; T Nakagoe
Journal:  J Gastroenterol       Date:  1995-04       Impact factor: 7.527

7.  Large bowel mucosal dysplasia and carcinoma in ulcerative colitis.

Authors:  D C Allen; J D Biggart; P C Pyper
Journal:  J Clin Pathol       Date:  1985-01       Impact factor: 3.411

8.  Surveillance in ulcerative colitis: burdens and benefit.

Authors:  H W Jones; J Grogono; A M Hoare
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

9.  Telomere shortening correlates to dysplasia but not to DNA aneuploidy in longstanding ulcerative colitis.

Authors:  Mariann Friis-Ottessen; Laila Bendix; Steen Kølvraa; Solveig Norheim-Andersen; Paula M De Angelis; Ole Petter F Clausen
Journal:  BMC Gastroenterol       Date:  2014-01-09       Impact factor: 3.067

10.  Flow cytometric DNA ploidy pattern in dysplastic mucosa, and in primary and metastatic carcinomas in patients with longstanding ulcerative colitis.

Authors:  G I Meling; O P Clausen; A Bergan; A Schjølberg; T O Rognum
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.